Nyrada

2 December 2020

Sydney, Australia

Cleansing Statement

Sydney, 2 December 2020: Nyrada Inc (ASX: NYR), issued further to the Appendix 2A lodged on 2 December 2020:

• 86,901 CHESS Depositary Interests (CDIs) from the exercise of 86,901 Convertible Note options (ASX: NYRAD).

NYR gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

- 1 The CDIs were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- 2 As at the date of this notice, NYR has complied with:
 - (a) The provisions of Chapter 2M of the Corporations Act as they apply to NYR; and
 - (b) Section 674 of the Corporations Act.
- 3 As at the date of this notice, there is no information that is "excluded information" of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

For and on behalf of the Board,

Yours faithfully,

David Franks Company Secretary

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological, and inflammatory/autoimmune diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

-ENDS-

Authorised by Mr John Moore, Non-Executive Chairman, on behalf of the Board.



www.nyrada.com

Investor & Corporate Enquiries:

Prue Kelly T: 0459 022 445 E: info@nyrada.com

Media Enquiries:

Catherine Strong Citadel-MAGNUS T: 02 8234 0111 E: cstrong@citadelmagnus.com

Company Secretary: David Franks

T: 02 8072 1400 E: David.Franks@automicgroup.com.au